FAH and Hepatic failure: This liver‐targeting strategy was also found to be suitable for the treatment of hepatorenal tyrosinemia type 1, which is caused by mutations in the fumarylacetoacetate hydrolase (FAH) enzyme and can result in severe complications such as liver failure.[184] In this case, a dendrimer LNP was used to deliver FAH mRNA via intravenous injection, protecting FAH–/– mice from rapid weight loss and reducing liver damage markers.